Formulary - Drug-related clinical news & analysis for hospital & managed-care P&T members

ADVERTISEMENT

Previous StoryPlay / PauseNext Story
Focus On . . .
Linaclotide: A guanylate cyclase type-C agonist for the treatment of constipation-predominant irritable bowel syndrome and chronic constipation
Constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation affect millions of Americans. Use of agents currently available for treatment is not supported by well-controlled clinical studies. A new drug application for linaclotide, an orally administered guanylate cyclase type-C receptor agonist for treatment of IBS-C and chronic constipation, was submitted to the US Food and Drug Administration (FDA) with a target action date of June 2012.
Clinical News
New guidelines recommend blood-glucose testing for all hospitalized patients
The Endocrine Society recently released new clinical practice guidelines recommending that all patients have their blood-glucose levels tested upon admission to the hospital, even if they haven’t been diagnosed with diabetes.
Study raises questions about aspirin as primary prevention for CVD
Aspirin prophylaxis in people without prior cardiovascular disease does not appear to reduce cardiovascular death or cancer mortality, according to the results of a meta-analysis published online January 9 in the Archives of Internal Medicine.
Statin use among older women may increase DM risk
Older women who use statins may be at an increased risk for diabetes mellitus, according to the results of a study published online January 9, in the Archives of Internal Medicine.

ADVERTISEMENT

Formulary Issue
Stay connected to Formulary
Receive web-exclusive articles, clinical news, and conference updates!
Newsletter signup
SUGGESTION BOX
Click here to leave a comment in our suggestion box.

Modern Medicine logoFormulary archives are now available on ModernMedicine.com, a new online resource designed to meet the evolving needs of physicians.
Register now (it's free and quick) or Find out more.

Keep visiting FormularyJournal.com for fresh content, news, opinions, editor's blogs and more.

MEDWATCH DRUG SAFETY UPDATES
Tysabri (natalizumab): Drug Safety Communication - New Risk Factor for Progressive Multifocal Leukoencephalopathy (PML)
Perfect Image Solutions Topical Hair Regrowth Products: Recall - Unapproved Drugs, Risk of Health Hazards
Vagifresh Ball, Vagifresh Gel, Female One: Recall - Undeclared Drug Ingredient, Bacterial Contamination
Adcetris (brentuximab vedotin): Drug Safety Communication - Progressive Multifocal Leukoencephalopathy and Pulmonary Toxicity
CardioGen-82 PET Scan: Drug Safety Communication - Increased Radiation Exposure

Last updated on Fri Jan 20 17:30:00 EST 2012

FORMULARY SURVEY OF THE MONTH
With the recent termination of the ALTITUDE trial due to increased risk of serious adverse events (non-fatal stroke, renal complications, hyperkalemia, and hypotension) in high-risk patients receiving aliskiren in combination with an ACE inhibitor or ARB medication, which of the following best describes the actions you deem most appropriate for managing the use of aliskiren-containing medications?
Immediately remove all aliskiren-based products from formulary and recommend switching patients to alternative anti-hypertensive medications
Maintain formulary status of aliskiren-based products, but perform RetroDUR to identify and communicate to providers of ALL patients on an aliskiren product
Maintain formulary status of aliskiren-based products, but perform RetroDUR to identify and communicate to providers of only high-risk patients on such an aliskiren combo
Implement new prior authorization and/or new contingent therapy edits on aliskiren products to minimize new patient starts on such combinations
Do nothing for the time-being until more definitive direction is provided from FDA
Immediately remove all aliskiren-based products from formulary and recommend switching patients to alternative anti-hypertensive medications
23%
Maintain formulary status of aliskiren-based products, but perform RetroDUR to identify and communicate to providers of ALL patients on an aliskiren product
21%
Maintain formulary status of aliskiren-based products, but perform RetroDUR to identify and communicate to providers of only high-risk patients on such an aliskiren combo
21%
Implement new prior authorization and/or new contingent therapy edits on aliskiren products to minimize new patient starts on such combinations
14%
Do nothing for the time-being until more definitive direction is provided from FDA
21%
View Results
Clinical Perspectives
AcneAdolescent MedicineAllergy & ImmunologyAlzheimer's DiseaseAsthmaBPHBreast CancerCardiologyCataractsChild Behavior & DevelopmentClinical PharmacologyContraceptionCorneal DiseaseCosmetic DermatologyCosmetic SurgeryDepressionDermatologyDiabetesDry EyeEczema/Atopic DermatitisEndocrinologyEpilepsyErectile DysfunctionGastroenterologyGastroesophageal Reflux Disease (GERD) & Acid Peptic DiseaseGeriatricsGlaucomaGynecologic OncologyHIV/AIDSHormone TherapyHyperlipidemiaHypertensionImmunization/VaccinesInfectious DiseaseInternal MedicineIrritable Bowel Syndrome (IBS)Kidney & Bladder CancerLaser & Light Technology in DermatologyMaternal & Fetal MedicineMenopauseMigraineMultiple SclerosisNeurologyNutritionOb/Gyn SurgeryObesityOB/GYN & Women's HealthOncologyOphthalmologyOptometryOrthopedicsOsteoporosisParkinson's DiseasePathologyPediatricsPrimary Care MedicineProstate CancerPsoriasisPsychiatry & Behavioral Health RadiologyRefractive SurgeryReproductive Endocrinology/InfertilityRetinal DiseaseRheumatoid ArthritisSkin CancerSleep DisordersSmoking-Related IllnessStrokeSurgeryUrinary Incontinence/Overactive BladderUrologic SurgeryUrology
Business Perspectives
Coding CounselorLiability & Risk ManagementHealth Care Information TechnologyPractice ManagementBusiness OperationsHuman ResourcesHealth Law & PolicyManaged CarePersonal FinanceProducts
Popular Topics
CME/CECoding CounselorEczema: Emollients, Counseling, and CareFind Resources to Help Manage Plaque Psoriasis Effectively [SPONSORED]Oral Anticoagulation in Atrial FibrillationEHR Technology eNewslettersGERD Resources for Your Practice and Patients [SPONSORED]Find Resources to Help Inform Patients on Managing Their IOP [SPONSORED]Find Resources to Help with Cataract Procedures [SPONSORED]Learn about Wavefront Technology in Progressive Lenses [SPONSORED]Help Prevent SREs in Your Patients with Bone Metastases [SPONSORED]Rx Adherence ToolAHA 2010 Video ReportsSurgery as Early Intervention in Morbid ObesityPatient Education CenterFracture Risk in Postmenopausal WomenBlogsSpecial Reports from The National Center for Children in Poverty (NCCP) DiscussionsModernMedicine RadioClinical Reference ManualsSyndicationSurgical Video Center


ADVERTISEMENT

Modern Medicine is a new online resource designed to meet the evolving needs of physicians. It brings together elements from Advanstar's trusted healthcare journals along with powerful tools, resources, decision support and advisory functions.

Click here